CytoReason: Machine-Learning Findings Reveal New Information That Might Lead to Improved Immunotherapy for Refractory Melanoma Patients

New findings presented on 10/16/18 by CytoReason reveals possible new cellular players in the tumor microenvironment that could impact the treatment process for the most in-need patients – those who have already failed to respond to ipilimumab (anti-CTLA4) immunotherapy.